Compare NTB & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTB | TARS |
|---|---|---|
| Founded | 1858 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2016 | 2020 |
| Metric | NTB | TARS |
|---|---|---|
| Price | $60.83 | $70.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $53.75 | ★ $89.00 |
| AVG Volume (30 Days) | 214.6K | ★ 890.8K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $0.84 | $56.43 |
| Revenue Next Year | $4.16 | $30.19 |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $40.59 | $38.51 |
| 52 Week High | $61.11 | $85.25 |
| Indicator | NTB | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 64.49 |
| Support Level | $57.71 | $59.60 |
| Resistance Level | N/A | $77.35 |
| Average True Range (ATR) | 1.02 | 3.77 |
| MACD | 0.08 | 0.62 |
| Stochastic Oscillator | 91.78 | 83.68 |
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It offers banking services, comprising retail and corporate banking, and wealth management services, which consist of trust, private banking, and asset management business. The company operates through four reportable segments: Bermuda, Cayman, Channel Islands and the UK, and Other. In its Bermuda and Cayman segments, the company offers retail banking and wealth management services. In the Channel Islands and the UK segment, the company offers retail and corporate banking and wealth management services, and the Other segment includes its operations in the Bahamas, Canada, Mauritius, Singapore, and Switzerland. Maximum revenue for the company is generated from its business in Bermuda.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.